A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...
Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...
GlaxoSmithKline bought Sierra Oncology for momelotinib, a candidate that recently passed a phase III trial for a rare bone marrow cancer. Myelofibrosis affects around 20,000 people in the USA. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback